

# **Thinking Outside the “Flow-Mediated” Box: An Analysis of Aortic Dilation in 100 Fetuses with Tetralogy of Fallot Compared to Matched Controls**

Authors: Minnie N Dasgupta MD<sup>a</sup>, Michelle A Kaplinski MD<sup>a</sup>, Charitha D Reddy MD<sup>a</sup>, and R Thomas Collins MD<sup>b</sup>

a - Department of Pediatrics (Division of Cardiology), Stanford University

750 Welch Road, Suite 305. Palo Alto, CA 94304-5731, USA.

b – Department of Pediatrics (Division of Cardiology), University of Kentucky

138 Leader Ave, Lexington, KY 40506, USA

[mdasgupta@stanford.edu](mailto:mdasgupta@stanford.edu); [mkaplinski@stanford.edu](mailto:mkaplinski@stanford.edu); [redduc@stanford.edu](mailto:redduc@stanford.edu);

[tomcollins@uky.edu](mailto:tomcollins@uky.edu)

Short Title: Aortic Dilation in Fetal Tetralogy of Fallot

Corresponding Author:

Minnie N. Dasgupta, MD

750 Welch Road, Suite 305, Palo Alto, CA 94304-5731

Phone: 650-721-6849; Fax: 650-725-8343

[mdasgupta@stanford.edu](mailto:mdasgupta@stanford.edu)

Total manuscript word count: 5,354

## ABSTRACT (Word Count: 250)

**Background:** Aortic dilation in tetralogy of Fallot (TOF) is primarily attributed to increased aortic flow *in utero*. An alternative hypothesis is abnormal neural crest cell migration, with unequal septation of the truncus arteriosus resulting in a larger aorta and inherently hypoplastic pulmonary artery (PA). If so, we hypothesize the aorta to PA ratio (Ao:PA) in TOF is stable throughout gestation, and the total sum of dimensions of the great arteries is similar to controls.

**Methods:** We performed a single-center retrospective study of all fetuses with TOF (2014-2020) and gestational age-matched controls. We compared sums of diameters, circumferences, and cross-sectional areas of the aorta and PA and evaluated the Ao:PA across gestation in TOF with pulmonary stenosis (TOF-PS) and atresia (TOF-PA). We analyzed data with two-tailed t-tests and Pearson's correlation. **Results:** There were 100 fetuses with TOF (36% TOF-PA) with median gestational age of 31 weeks [IQR 26.5, 34.4] and median maternal age of 34 years [IQR 30, 37]. There were no differences in sums of great artery dimensions between TOF-PS and controls. In TOF-PA, sums were significantly lower than controls. The Ao:PA was stable throughout gestation. **Conclusions:** The aorta in fetal TOF is large but grows proportionally throughout gestation, with a sum of great artery dimensions similar to controls. TOF-PA appears to be distinct from TOF-PS (with overall smaller dimensions), and is a group that warrants further investigation. In conclusion, our findings do not support the flow-mediated model of aortic dilation in TOF, and instead suggest an intrinsic developmental mechanism.

[Keywords: tetralogy of Fallot, aortic dilation, fetal echocardiogram]

## Clinical Perspective

### What's New?

- The aorta in fetal Tetralogy of Fallot (TOF) is large, but grows proportionally throughout gestation with a total sum of great artery dimensions similar to controls.
- Fetuses with TOF with pulmonary atresia have smaller great artery dimensions than TOF with pulmonary stenosis; this distinct group warrants further investigation.
- Our findings suggest that aortic dilation in TOF may be secondary to an intrinsic developmental mechanism, rather than from increased flow to the aorta *in utero*.

### What are the clinical implications?

- The mechanisms of aortic dilation in fetal TOF have not been previously investigated.
- While aortic dilation is commonly seen in TOF, the degree of its progression over time and risk of dissection are not well understood.
- A better understanding of the etiology of aortic dilation in TOF could help to inform management decisions, particularly regarding the need for prophylactic surgical repair.

## Introduction

Aortic root dilation in tetralogy of Fallot (TOF) is a well-described phenomenon, from its use as a tool for identification *in utero* to late persistence following repair<sup>1,2</sup>. Compared to controls, patients with conotruncal defects have enlarged aortic valve and root diameters and increased aortic-to-pulmonary valve ratios<sup>3,4</sup>. Due to these characteristics, initial prenatal screening for TOF includes evaluating the relative sizes of the aorta and pulmonary artery<sup>5,6</sup>. There are multiple theories regarding the underlying mechanism of aortic dilation in TOF. The prevailing theory is flow-mediated, in which increased aortic flow *in utero* causes dilation. This is supported by data showing an inverse relationship between aortic size and size of the right ventricular outflow tract<sup>2,7</sup>. However, a lack of correlation between pulmonary artery and aortic sizes in other studies suggests the great arteries may not respond proportionately to changes in flow<sup>8</sup>. In fact, histologic abnormalities of the aorta (elastic fragmentation, medial necrosis and ground substance changes) have been reported in TOF<sup>9,10</sup>. These imply the aorta in TOF may be intrinsically predisposed to dilate, as in aortopathy syndromes<sup>11–13</sup>. Lastly, there are associations between 22q11.2 deletion and risk of aortic dilation in TOF, suggestive of a possible genetic predisposition<sup>14,15</sup>. Many have stressed the importance of understanding nuanced environmental and genetic contributors to congenital heart disease, as opposed to reliance on morphologic and hemodynamic models alone<sup>16,17</sup>. While there have been intentional investigations (with variable results) into the flow-mediated hypotheses of other lesions such as hypoplastic left heart syndrome, there has yet to be a formal study of such mechanisms in TOF<sup>18–23</sup>.

Thus, the objective of this study was to begin a preliminary investigation into a potential developmental etiology of aortic dilation in TOF. It is well established that the embryologic truncus arteriosus forms from neural crest cells and undergoes septation<sup>24–26</sup>. In TOF, neural

crest cell development and migration may be altered<sup>27,28</sup>. Theoretically, abnormal septation causes fewer cells to migrate to the pulmonary artery, thus making it inherently hypoplastic and deviating the conal septum anteriorly. In this model, aortic enlargement in TOF results from a greater percentage of common truncal cells committing to the aorta than to the pulmonary artery. We chose to investigate the dimensional relationship of the great arteries across gestation. We hypothesized if the aorta-to-pulmonary artery ratio (Ao:PA) is stable throughout gestation, and total dimensions of the two great arteries are similar to gestational-age matched controls, then aortic dilation in TOF may be developmental, resulting from the uneven division of the common truncus arteriosus (Figure 1A). Conversely, if aortic dilation is primarily due to increased flow, longer exposure to increased flow throughout gestation should increase the Ao:PA over time and the total great artery dimensions would vary depending on individual flow ratios (Figure 1B).

## Methods

We performed a single-center retrospective analysis of all fetuses with TOF evaluated from December 2014 to December 2020 at the Lucile Packard Children's Hospital Stanford. A control group was randomly selected from a large group of fetuses with normal intracardiac anatomy who were matched by equal gestational age (in weeks) and year of study. All fetal echocardiograms were stored on our institution's secure server syngoDynamics (Siemens Medical Solutions USA; syngoDynamics Solutions, Ann Arbor, MI) with original images acquired by either an American Registry for Diagnostic Medical Sonography certified fetal sonographer or by a fetal cardiologist. If a single fetus had more than one echocardiogram available for analysis, the first and the last (chronological) studies were included as unique entries in the cohort. This was done to incorporate the possibility of changes within a single fetus

across gestation. We excluded all fetuses with absent pulmonary valve syndrome, severe pulmonary insufficiency, “TOF type” double-outlet right ventricle, TOF-associated with atrioventricular canal defects or other forms of congenital heart disease, and those in whom essential cardiac structures could not be appropriately visualized. All fetuses had confirmatory postnatal imaging solidifying the fetal diagnosis, and studies were excluded when postnatal imaging was not available or if the pregnancy was terminated. The final group consisted of 100 fetuses with TOF and 100 matched controls. Of note, all control echocardiograms came from unique fetuses. The reported presence of pulmonary atresia in TOF is 10-20% in the general TOF population, but was notably high (36%) at our institution<sup>29,30</sup>. We therefore decided to analyze TOF in the form of three cohorts, based on severity of right ventricular outflow tract obstruction. The first cohort was fetuses with TOF with pulmonary stenosis (TOF-PS) (n = 64), the second cohort was fetuses with TOF with pulmonary atresia (TOF-PA) (n = 36), and the third cohort was all fetuses with TOF, including TOF-PS or TOF-PA (n = 100).

The primary investigator (MND) made all offline measurements using the syngoDynamics workstation with 20% of randomly selected studies independently measured by the second author (MAK) for interobserver agreement. The second reader was blinded to initial analysis and subsequent interobserver variance was within 10% for all measurements. Echocardiographic measurements for this study included diameters of the aortic valve annulus, pulmonary valve annulus, ascending aorta, and main pulmonary artery. The ascending aorta was measured from both the transverse left ventricular outflow tract view and the sagittal aortic arch view, with the larger of the two measurements included for interpretation<sup>31</sup>. When possible, the ascending aorta was measured at approximately the level of the takeoff of the right pulmonary artery. The main pulmonary artery measurement was made just distal to the pulmonary valve

when visualized. In fetuses with TOF-PA, our investigators still measured a pulmonary valve annulus size (at the valve hinge points) and branch pulmonary artery size if any valve tissue or branch pulmonary arteries, whether confluent or non-confluent, were appreciated. Patients with no appreciable pulmonary valve on fetal imaging were included in the study with a pulmonary valve annulus diameter of zero if postnatal imaging also confirmed the lack of pulmonary valve tissue. Lastly, the sex, maternal age, gestational age, biometry, and postnatal diagnosis were obtained both from the secure server and corroborated with data from the electronic medical record. Maternal race/ethnicity was also reported, in the specific categories offered for patients to select at our individual institution.

Raw data in the form of primary echocardiographic measurements were expressed in centimeters (cm). To provide multiple measures of great artery size, we calculated the sums of the diameters (cm), circumferences (cm), and cross sectional-areas (cm<sup>2</sup>) of the aortic and pulmonary valves, as well as the ascending aorta and main pulmonary artery. Given the normal distribution of data, we used Student two-tailed *t*-tests with equal population size and variance to compare the total great artery parameters between fetuses with TOF and normal controls. This analysis was performed for the TOF-PS group (*n* = 64), the TOF-PA group (*n* = 36), and then for the TOF-PS and TOF-PA combined group (*n* = 100). A *p*-value of < 0.05 was considered statistically significant to reject the null hypothesis that the total great artery parameters were equal. We also calculated the Ao:PA at both the valvar and proximal great artery levels. To assess these ratios over gestational age we used the Pearson correlation coefficient (Pearson's *r*) to measure linear correlation, in which a value of 0 implies no linear dependency between two variables. Author MND had full access to all data in the study and attests to its integrity and the

data analysis. The protocol for this study was approved by Stanford University's Institutional Review Board Panel on Medical Human Subjects (protocol #50981).

## Results

One hundred fetal TOF echocardiograms and 100 normal fetal echocardiograms met inclusion criteria and made up the study cohort. The median gestational age was 31 weeks [IQR 26.5, 34.4] in both groups. There were no significant differences in baseline sex distribution, maternal age, or gestational age between groups (Table 1). Among the 100 TOF studies, there were 73 individual fetuses. Sixty-four fetal echocardiograms demonstrated TOF-PS and 36 demonstrated TOF-PA.

Raw data were collected in the form of great artery measurements for all fetuses (Table 2). As shown in Table 3, there were no differences in the mean sums of the study measurements between TOF-PS ( $n = 64$ ) and controls at the valvar or proximal great artery level. The mean sums were significantly lower in TOF-PA ( $n = 36$ ) compared to controls for the diameters, circumferences, and cross-sectional areas at the valvar level, and the mean sums of the diameters and circumferences at the proximal great artery level. There was no difference in the mean sums of the cross-sectional areas at the proximal great artery level. The analysis for the full TOF cohort ( $n = 100$ ) mirrored the findings of the TOF-PA cohort.

The Ao:PA in fetuses with TOF did not increase with increasing gestational age, with a Pearson correlation coefficient  $r$  of 0.08 (Figure 2A). Likewise, the ascending aorta to main pulmonary artery ratio in fetuses with TOF did not increase, with a Pearson correlation coefficient  $r$  of -0.06 (Figure 2B). Those with no pulmonary valve tissue (pulmonary valve = 0



cm) and no main pulmonary artery segment (main pulmonary artery = 0 cm) were excluded from ratio calculations, to avoid the use of a denominator of zero.

## Discussion

This study represents one of the largest single-center cohorts of fetal TOF to date<sup>32</sup>. Our study sought to investigate a potential developmental etiology of aortic dilation in TOF and has three notable findings. There were no significant differences in the sums of the great artery dimensions (diameters, circumferences, and cross-sectional areas) between TOF-PS fetuses and gestational age-matched controls at the valvar or great artery level. Throughout the observed period of gestation, the Ao:PA at both measurement levels did not change. Lastly, when evaluating fetuses with TOF-PA as a unique entity, the great artery study parameters were significantly smaller than either TOF-PS or normal matched controls.

Although aortic dilation is well-described in TOF, its degree of progression and risk of aortic dissection are less well understood, with mixed data on progressive aortic changes after initial repair<sup>1,33–36</sup>. Overall, in large population-based studies, the risk of aortic dissection in conotruncal defects including TOF is exceedingly rare<sup>37,38</sup>. While catastrophic dissection in TOF is described in case reports and must be taken seriously to enable prevention, a better understanding of the etiology of aortic dilation in TOF would be helpful to explain the discrepancy in dissection rates from classic aortopathy syndromes, as well as to inform management decisions regarding the need for prophylactic surgical repair. Although this has not been previously investigated in a TOF cohort, perhaps the closest parallel theories that have been formally researched are in hypoplastic left heart syndrome, a lesion in which there are also two contrasting theories of underlying pathogenesis. Some animal studies have shown that the

intentional reduction of flow across the mitral and aortic valve in fetal life can lead to the development of HLHS<sup>18–20</sup>. However, others have shown that there can be clinically significant left ventricular hypoplasia without associated valvar stenosis, more suggestive of a primary disturbance of cardiomyocytes mirroring a cardiomyopathy syndrome<sup>21–23</sup>. Similar to the argument made for understanding HLHS pathology, a stronger grasp of the etiologies of aortic dilation in TOF could better guide future investigations. To begin to understand potential contributors to aortic dilation in TOF specifically, we chose to use the sum of great artery dimensions, which is a novel method of investigating the etiology of aortic dilation in TOF. This design stems from the importance of the embryologic truncus arteriosus, which serves as the precursor to both the aorta and pulmonary artery (Figure 1A). To our knowledge, ours is the first human fetal study investigating the Ao:PA as an indicator of the septation patterns of the truncus arteriosus in TOF development. Interestingly, we found no significant differences in great artery dimension sums between TOF-PS and controls. While a flow-mediated mechanism would produce different dimension sums that vary by individual flow ratio (Figure 1B), our findings prompt the question of whether unequal truncal division in TOF may be a determinant of aortic dilation. Given this question, there remains a need for more detailed cellular analysis which could ultimately impact evidence-based guidelines on the appropriate frequency of monitoring aortic dimensions and thresholds for intervention in this cohort.

An Ao:PA greater than one is associated with TOF at any stage, but has not been previously assessed throughout gestation in such a large cohort. The general finding of enlarged aortic root dimensions compared to normal has long been an early marker for fetal diagnosis of TOF<sup>5,39</sup>. More specifically, an Ao:PA greater than one is frequently used for diagnosis of conotruncal defects<sup>6,40</sup>. Our study shows a stable Ao:PA at two defined levels (valvar and above)

throughout gestation. If aortic dilation in TOF were purely flow mediated, we would expect that longer exposure to increased flow throughout gestation would subsequently increase the Ao:PA over time. The results of our study also suggest that if abnormal truncal septation plays a potential role in aortic size in TOF, an Ao:PA ratio greater than one should be apparent from quite early in gestation (theoretically, as soon as conotruncal division occurs). This second important finding again argues against the predominantly accepted flow-mediated mechanism.

As we know, TOF-PA represents the most severe form of TOF. Though the typical incidence of pulmonary atresia in TOF is 10-20%, as a large referral center for TOF-PA, our sample was skewed toward fetuses with pulmonary atresia<sup>29,30</sup>. Given this atypical distribution, we ultimately opted to analyze TOF in three different cohorts, as described above. Somewhat surprisingly, when including TOF-PA patients in our analysis, we found that the sums of the great artery dimensions were significantly lower than in TOF-PS fetuses and in matched controls. This was true for all parameters, with the exception of the sum of the cross-sectional areas (at the ascending aorta and main pulmonary artery level only). This unexpected finding in one parameter may be due to differences in severity of hypoplasia in the pulmonary valve as opposed to the main pulmonary artery, but warrants further consideration. In regards to the general fetal development of great arteries, it is well established that cardiac neural crest cells play an essential role in the normal development of the embryologic truncus arteriosus and its septation into the aorta and pulmonary artery. Animal models have shown that neural crest cell ablation and thus interruption of associated signaling during development leads to a broad spectrum of outflow tract abnormalities such as TOF<sup>41-43</sup>. The smaller dimensions seen in TOF-PA as compared to TOF-PS and normal controls is a new finding and perhaps represents a different underlying pathology altogether. Though we did not assay neural crest cell numbers in

this study, one might theorize an underlying deficiency in the initial neural crest cell population that composes the common truncus in TOF-PA. If so, the common truncus may never grow to the same initial dimensions in a pulmonary atresia cohort. Since this remains theoretical, more targeted investigations are needed to better understand the molecular genetics of pulmonary atresia. However, our findings do prompt the question of whether TOF-PA may be a unique entity with a different developmental pattern from TOF with some component of antegrade flow.

There are several limitations to our study, including that it is a retrospective analysis from a single-center institution. A number of fetal studies were excluded due to poor image quality or lack of available postnatal imaging to confirm diagnosis. Standards of fetal biometry characterization also changed over the course of our study period, and data were not always available in a consistent manner from year-to-year. As a result, prior to 2016, gestational age is based on reported dates as opposed to those after 2016 which were calculated primarily on biometry; there can be significant differences between these methods of estimating age. Based on the capabilities of fetal echocardiogram, it is important to note that we were only able to assess data past approximately 18 weeks of gestation and cannot comment on changes in great artery size or ratio in earlier stages of embryologic development. In the absence of reviewing serial fetal echocardiograms for all cases in the cohort, we were also unable to specifically assess the progression of great artery sizes and ratios within each individual fetus. Other than differentiating between fetuses with and without pulmonary atresia, we did not evaluate other factors that may impact TOF physiology and variability of aortic dilation, such as streaming tendencies, degree of aortic override, or genetic conditions. Lastly, we did not evaluate post-natal outcomes or ongoing changes in great artery size in response to interventions on the right ventricular outflow tract. Several of the above limitations could be improved upon or further

investigated in future versions of this study, perhaps involving serial non-invasive imaging and histology to confirm our suggested hypotheses (particularly in the postnatal period).

In conclusion, aortic dilation in TOF is well-described, but its etiology remains poorly understood with a prevailing theory of flow-mediated growth. We used a novel methodology to assess sums of great artery dimensions in utero, and found no significant differences in the sums of great artery dimensions between TOF-PS and matched controls. The Ao:PA at multiple levels also did not change throughout gestation. These findings suggest there may be a developmental component of aortic dilation in TOF, and this theory warrants further investigation.

## Acknowledgments, Sources of Funding, & Disclosures

Statement of Financial Support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declarations or Disclosures of Interest: None.

Consent Statement: Per Stanford University's Institutional Review Board, individual patient consent was waived for this retrospective study.

## References


1. Woudstra OI, Ghanam A, Vliegen HW, Dijk APJ van, Melle JP van, Groenink M, Meijboom FJ, Post MC, Mulder BJM, Bouma BJ, Bokma JP. The aortic root in repaired tetralogy of Fallot: Serial measurements and impact of losartan treatment. *Int J Cardiol* 2021;326:88–91.
2. Niwa K, Siu SC, Webb GD, Gatzoulis MA. Progressive Aortic Root Dilatation in Adults Late After Repair of Tetralogy of Fallot. *Circulation* 2002;106:1374–1378.
3. Jatavan P, Tongprasert F, Srisupundit K, Luewan S, Traisrisilp K, Tongsong T. Quantitative Cardiac Assessment in Fetal Tetralogy of Fallot. *J Ultrasound Med* 2016;35:1481–1488.
4. Wang Q, Zhao Y, Han L, Zhang Y, Ge S, He Y. Pulmonary hypoplasia in fetuses with congenital conotruncal defects. *Echocardiography* 2017;34:1842–1851.
5. DeVore GR, Siassi B, Platt LD. Fetal echocardiography. *Am J Obstet Gynecol* 1988;159:129–136.
6. Rollins RC, Acherman RJ, Castillo WJ, Evans WN, Restrepo H. Aorta Larger Than Pulmonary Artery in the Fetal 3-Vessel View. *J Ultrasound Med* 2009;28:9–12.
7. Marelli AJ, Perloff JK, Child JS, Laks H. Pulmonary atresia with ventricular septal defect in adults. *Circulation* 1994;89:243–251.
8. Hornberger LK, Sanders SP, Sahn DJ, Rice MJ, Spevak PJ, Benacerraf BR, McDonald RW, Colan SD. In utero pulmonary artery and aortic growth and potential for progression of pulmonary outflow tract obstruction in tetralogy of Fallot. *J Am Coll Cardiol* 1995;25:739–745.
9. Tan JL, Davlouros PA, McCarthy KP, Gatzoulis MA, Ho SY. Intrinsic Histological Abnormalities of Aortic Root and Ascending Aorta in Tetralogy of Fallot: Evidence of Causative Mechanism for Aortic Dilatation and Aortopathy. *Circulation* 2005;112:961–968.
10. Chowdhury UK, Mishra AK, Balakrishnan P, Sharma S, Kabra M, Ray R, Kalaivani M, Gupta R, Govindappa RM, Subramaniam GK. Role of fibrillin-1 genetic mutations and polymorphism in aortic dilatation in patients undergoing intracardiac repair of tetralogy of Fallot. *J Thorac Cardiovasc Surg* 2008;136:757-766.e10.
11. Taketazu M, Sugimoto M, Saiki H, Ishido H, Masutani S, Senzaki H. Developmental Changes in Aortic Mechanical Properties in Normal Fetuses and Fetuses with Cardiovascular Disease. *Pediatr Neonatol* 2017;58:245–250.
12. Saiki H, Kojima T, Seki M, Masutani S, Senzaki H. Marked disparity in mechanical wall properties between ascending and descending aorta in patients with tetralogy of Fallot. *Eur J Cardiothorac Surg* 2012;41:570–573.
13. Seki M, Kuwata S, Kurishima C, Nakagawa R, Inuzuka R, Sugimoto M, Saiki H, Iwamoto Y, Ishido H, Masutani S, Senzaki H. Mechanism of aortic root dilation and cardiovascular function in tetralogy of Fallot: Aortic root dilation in TOF. *Pediatr Int* 2016;58:323–330.

14. John AS, Rychik J, Khan M, Yang W, Goldmuntz E. 22q11.2 deletion syndrome as a risk factor for aortic root dilation in tetralogy of Fallot. *Cardiol Young* 2014;24:303–310.
15. John AS, McDonald-McGinn DM, Zackai EH, Goldmuntz E. Aortic root dilation in patients with 22q11.2 deletion syndrome. *Am J Med Genet A* 2009;149A:939–942.
16. Gelb BD. History of Our Understanding of the Causes of Congenital Heart Disease. *Circ Cardiovasc Genet* 2015;8:529–536.
17. Nora JJ. Multifactorial inheritance hypothesis for the etiology of congenital heart diseases. The genetic-environmental interaction. *Circulation* 1968;38:604–617.
18. Rahman A, Chaturvedi RR, Sled JG. Flow-Mediated Factors in the Pathogenesis of Hypoplastic Left Heart Syndrome. *J Cardiovasc Dev Dis* 2022;9:154.
19. Pesevski Z, Kvasilova A, Stopkova T, Nanka O, Drobna Krejci E, Buffinton C, Kockova R, Eckhardt A, Sedmera D. Endocardial Fibroelastosis is Secondary to Hemodynamic Alterations in the Chick Embryonic Model of Hypoplastic Left Heart Syndrome. *Dev Dyn Off Publ Am Assoc Anat* 2018;247:509–520.
20. Wong FY, Veldman A, Sasi A, Teoh M, Edwards A, Chan Y, Graupner O, Enzensberger C, Axt-Flidner R, Black MJ, Schranz D. Induction of left ventricular hypoplasia by occluding the foramen ovale in the fetal lamb. *Sci Rep* 2020;10:880.
21. Grossfeld P, Nie S, Lin L, Wang L, Anderson RH. Hypoplastic Left Heart Syndrome: A New Paradigm for an Old Disease? *J Cardiovasc Dev Dis* 2019;6:10.
22. Gardner MM, Cohen MS. Clinical findings in right ventricular noncompaction in hypoplastic left heart syndrome. *Congenit Heart Dis* 2017;12:783–786.
23. Gaber N, Gagliardi M, Patel P, Kinnear C, Zhang C, Chitayat D, Shannon P, Jaeggi E, Tabori U, Keller G, Mital S. Fetal reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during cardiac differentiation. *Am J Pathol* 2013;183:720–734.
24. Keyte A, Hutson MR. The neural crest in cardiac congenital anomalies. *Differentiation* 2012;84:25–40.
25. Nakamura T, Gulick J, Colbert MC, Robbins J. Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development. *Proc Natl Acad Sci* 2009;106:11270–11275.
26. Conway S. Decreased neural crest stem cell expansion is responsible for the conotruncal heart defects within the Splotch (Sp2H)/Pax3 mouse mutant. *Cardiovasc Res* 2000;47:314–328.
27. Kirby ML, Waldo KL. Neural Crest and Cardiovascular Patterning. *Circ Res* 1995;77:211–215.




28. Kloesel B, DiNardo JA, Body SC. Cardiac Embryology and Molecular Mechanisms of Congenital Heart Disease: A Primer for Anesthesiologists. *Anesth Analg* 2016;123:551–569.
29. Murthy K, Reddy P, Nagarajan R, Goutami V, Cherian K. Management of ventricular septal defect with pulmonary atresia and major aorto pulmonary collateral arteries: Challenges and controversies. *Ann Pediatr Cardiol* 2010;3:127.
30. Allen HD, Shaddy RE, Penny DJ, Cetta F, Feltes TF. *Moss and Adams' heart disease in infants, children, and adolescents: including the fetus and young adult.*; 2016.
31. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W, Michelfelder EC, Rempel GR, Silverman NH, Spray TL, Strasburger JF, Tworetzky W, Rychik J. Diagnosis and Treatment of Fetal Cardiac Disease: A Scientific Statement From the American Heart Association. *Circulation* 2014;129:2183–2242.
32. Grzyb A, Koleśnik A, Bokiniec R, Szymkiewicz-Dangel J. Tetralogy of Fallot in the fetus - from diagnosis to delivery. 18-year experience of a tertiary Fetal Cardiology Center. *Kardiologia Polska* 2022.
33. Grotenhuis HB, Dallaire F, Verpalen IM, Akker MJE van den, Mertens L, Friedberg MK. Aortic Root Dilatation and Aortic-Related Complications in Children After Tetralogy of Fallot Repair. *Circ Cardiovasc Imaging* 2018;11:e007611.
34. François K, Zaout M, Bové T, Vandekerckhove K, De Groote K, Panzer J, De Wilde H, De Wolf D. The fate of the aortic root after early repair of tetralogy of Fallot. *Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg* 2010;37:1254–1258.
35. Siripornpitak S, Sriprachyakul A, Wongmetta S, Samankatiwat P, Mokarapong P, Wanitkun S. Follow-up aortic dilatation in patients with repaired tetralogy of Fallot using cardiovascular magnetic resonance. *Eur J Radiol Open* 2021;8:100354.
36. Sim HT, Kim J-W, Kim SH, Park S-J, Jang S-I, Lee C-H. Correlation Between Total Repair Timing and Late Aortic Root Dilatation in Repaired Tetralogy of Fallot. *Pediatr Cardiol* 2020;41:1501–1508.
37. Egbe AC, Crestanello J, Miranda WR, Connolly HM. Thoracic Aortic Dissection in Tetralogy of Fallot: A Review of the National Inpatient Sample Database. *J Am Heart Assoc* 2019;8:e011943.
38. Frischhertz BP, Shamszad P, Pedroza C, Milewicz DM, Morris SA. Thoracic aortic dissection and rupture in conotruncal cardiac defects: A population-based study. *Int J Cardiol* 2015;184:521–527.
39. Martínez JM, Gómez O, Bennasar M, Olivella A, Crispi F, Puerto B, Gratacós E. The “question mark” sign as a new ultrasound marker of tetralogy of Fallot in the fetus. *Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol* 2010;36:556–560.

40. Idilman IS, Ipek A, Balaban M, Keskin HL, Aypar E, Ozkutlu S. Fetal aorta larger than the main pulmonary artery on the three-vessel view: Correlation with postnatal echocardiographic findings. *J Clin Ultrasound JCU* 2016;44:423–428.
41. Aghajanian H, Cho YK, Rizer NW, Wang Q, Li L, Degenhardt K, Jain R. Pdgfr $\alpha$  functions in endothelial-derived cells to regulate neural crest cells and the development of the great arteries. *Dis Model Mech* 2017;10:1101–1108.
42. Darrigrand J-F, Valente M, Comai G, Martinez P, Petit M, Nishinakamura R, Osorio DS, Renault G, Marchiol C, Ribes V, Cadot B. Dullard-mediated Smad1/5/8 inhibition controls mouse cardiac neural crest cells condensation and outflow tract septation. *eLife* 2020;9:e50325.
43. Grunert M, Dorn C, Schueler M, Dunkel I, Schlesinger J, Mebus S, Alexi-Meskishvili V, Perrot A, Wassilew K, Timmermann B, Hetzer R, Berger F, Sperling SR. Rare and private variations in neural crest, apoptosis and sarcomere genes define the polygenic background of isolated Tetralogy of Fallot. *Hum Mol Genet* 2014;23:3115–3128.



**Figure 1. A)** A schematic in which a common truncus arteriosus divides equally into the pulmonary artery and aorta in a normal fetus, and unequally in a fetus with Tetralogy of Fallot. The total cross-sectional area remains the same in both scenarios. **B)** A schematic depicting the expected aortic size in a flow-mediated mechanism of aortic dilation, where  $Q_p$  represents blood flow through the pulmonary artery and  $Q_s$  represents blood flow through the aorta. The total cross-sectional area varies with the  $Q_p$  to  $Q_s$  ratio.



**Figure 2.** Scatter plots and associated Pearson correlation coefficients for the **A)** aortic valve to pulmonary valve ratio ( $r = 0.08$ ) and **B)** ascending aorta to main pulmonary artery ratio ( $r = 0.06$ ) throughout gestation in Tetralogy of Fallot.

**Table 1: Baseline demographics.**

Variable	Tetralogy of Fallot (%)	Control (%)
No. of Studies	100	100
Fetal Male Sex	56 (56)	52 (52)
Maternal Race/Ethnicity		
White/Caucasian	49 (49)	32 (32)
Asian	25 (25)	23 (23)
Hispanic/Latino	25 (25)	40 (40)
Hawaiian Native/Pacific Islander	1 (1)	0 (10)
Black/African American	0 (0)	3 (3)
Other/Unknown	0 (0)	2 (2)
Maternal Age (years)	34 [30, 37]*	33 [28.8, 36]*
Gestational Age (weeks)	31 [26.5, 34.4]*	31 [26.5, 34.4]*

**Table 1** Baseline demographics. Values for categorical variables are reported as number (percentage). \*For continuous variables, values are reported as median [interquartile range].

**Table 2: Great artery measurements.**

	Control (n = 100)	All TOF (n = 100)	TOF-PS (n = 64)	TOF-PA (n=36)
<b>Aortic Valve Size (cm)</b>	0.54 ± 0.13	0.70 ± 0.17	0.66 ± 0.17	0.77 ± 0.15
<b>Pulmonary Valve Size (cm)</b>	0.68 ± 0.17	0.31 ± 0.21	0.44 ± 0.11	0.07 ± 0.13
<b>Ascending Aorta Size (cm)</b>	0.59 ± 0.12	0.77 ± 0.19	0.71 ± 0.18	0.87 ± 0.16
<b>Main PA Size (cm)</b>	0.71 ± 0.18	0.40 ± 0.20	0.47 ± 0.15	0.23 ± 0.19

**Table 2** Great artery measurements. Values are reported as mean ± standard deviation.

**Table 3: Sums of great artery parameters.**

<b>Tetralogy of Fallot with Pulmonary Stenosis (n=64)</b>			
<b>Outcome</b>	<b>Control (Mean ± SD)</b>	<b>TOF -PS (Mean ± SD)</b>	<b>P-Value</b>
Aortic Valve/Pulmonary Valve			
Sum of Diameters (cm)	1.17 ± 0.28	1.09 ± 0.26	0.11
Sum of Circumferences (cm)	3.68 ± 0.87	3.43 ± 0.82	0.11
Sum of Cross-Sectional Areas (cm <sup>2</sup> )	0.57 ± 0.25	0.52 ± 0.23	0.20
Ascending Aorta/Main PA			
Sum of Diameters (cm)	1.24 ± 0.29	1.19 ± 0.30	0.30
Sum of Circumferences (cm)	3.91 ± 0.90	3.74 ± 0.95	0.30
Sum of Cross-Sectional Areas (cm <sup>2</sup> )	0.64 ± 0.28	0.62 ± 0.29	0.60
<b>Tetralogy of Fallot with Pulmonary Atresia (n=36)</b>			
<b>Outcome</b>	<b>Control (Mean ± SD)</b>	<b>TOF -PA (Mean ± SD)</b>	<b>P-Value</b>
Aortic Valve/Pulmonary Valve			
Sum of Diameters (cm)	1.36 ± 0.28	0.84 ± 0.19	< 0.01*
Sum of Circumferences (cm)	4.27 ± 0.87	2.64 ± 0.61	< 0.01*
Sum of Cross-Sectional Areas (cm <sup>2</sup> )	0.76 ± 0.29	0.50 ± 0.18	< 0.01*
Ascending Aorta/Main PA			
Sum of Diameters (cm)	1.39 ± 0.27	1.10 ± 0.26	< 0.01*
Sum of Circumferences (cm)	4.28 ± 0.86	3.45 ± 0.82	< 0.01*
Sum of Cross-Sectional Areas (cm <sup>2</sup> )	0.80 ± 0.30	0.68 ± 0.23	0.08
<b>Tetralogy of Fallot with Pulmonary Stenosis or Pulmonary Atresia (n=100)</b>			
<b>Outcome</b>	<b>Control (Mean ± SD)</b>	<b>All TOF (Mean ± SD)</b>	<b>P-Value</b>
Aortic Valve/Pulmonary Valve			
Sum of Diameters (cm)	1.24 ± 0.29	1.01 ± 0.27	< 0.01*
Sum of Circumferences (cm)	3.88 ± 0.91	3.17 ± 0.84	< 0.01*
Sum of Cross-Sectional Areas (cm <sup>2</sup> )	0.64 ± 0.28	0.51 ± 0.21	< 0.01*
Ascending Aorta/Main PA			
Sum of Diameters (cm)	1.29 ± 0.29	1.16 ± 0.29	< 0.01*
Sum of Circumferences (cm)	4.05 ± 0.90	3.65 ± 0.92	< 0.01*

Sum of Cross-Sectional Areas (cm <sup>2</sup> )	0.70 ± 0.29	0.64 ± 0.28	0.17
---	-------------	-------------	------

**Table 3** Sums of great artery parameters. Values are reported as mean ± standard deviation. A p-value of < 0.05 was considered statistically significant to reject the null hypothesis.